Sign up United Kingdom
Evgen Pharma (LON:EVG)

Evgen Pharma (LON:EVG)

Share Price
13.75 p
0 (0.00 %)
Market Cap
£12.84 m
Proactive Investors - Run By Investors For Investors

Evgen Pharma RNS Release

Upcoming Investor Presentations

RNS Number : 8887N
Evgen Pharma PLC
14 May 2018


For immediate release

14 May 2018









Evgen Pharma plc

 ("Evgen Pharma" or "the Company")


Upcoming Investor Presentations


Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that Dr Stephen Franklin, the Company's CEO, will present at a series of upcoming investor evenings.


The presentation will focus on the Phase II trials of SFX-01, the Company's lead product, in the treatment of breast cancer and subarachnoid haemorrhage, a type of stroke.


Investors and shareholders wishing to register for the investor presentations may do so through the links provided below.


16 May 2018 - ShareSoc Growth Company Seminar, London


Time: The presentation will start at 5.30pm followed by a buffet and refreshments.

Location: Link Asset Services, 65 Gresham Street, London, EC2V 7NQ.

Link to register:


17 May 2018 - Proactive Investors Healthcare, London


Time: The presentation will start at 6.00pm followed by drinks and canapés.

Location: Chesterfield Mayfair Hotel, 35 Charles Street, London, W1J 5EB. 

Link to register:


19 June 2018 - ShareSoc Growth Company Seminar, Manchester


Time: The presentation will start at 5.30pm followed by a buffet and refreshments.

Location: Kuits Solicitors, 7th Floor, Blackfriars House, Manchester, M3 2JA.

Link to register:


A copy of the latest investor presentation will be available from 12pm on 15 May 2018 at:


Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO

c/o +44 (0) 20 7466 5000





Mark Court, Sophie Wills, Stephanie Watson

+44 (0) 20 7466 5000




Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company focussed on the development of a new class of pharmaceutical; sulforaphane-based compounds for application in oncology and neurology markets.  Lead product, SFX-01, is in two Phase II trials, utilising two separate mechanistic targets, with expected read-outs around the end of 2018.

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit:

For commissioned research on the Company, please visit:


This information is provided by RNS
The company news service from the London Stock Exchange

Evgen Pharma Timeline

October 21 2015

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use